Drugs / 89Zr-TAK-164
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03449030 | Apr 2018 → Feb 2020 | digestive system cancer | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-TAK-164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03449030 ↗ |
| Modality | Diagnostic / imaging agent | “In Part C (Imaging substudy to be conducted in the Netherlands only), approximately 25 participants with GCC-expressing metastatic colorectal carcinoma (mCRC) will be enrolled...” NCT03449030 ↗ |
| Route | Intravenous | “89Zr-TAK-164 intravenous infusion” NCT03449030 ↗ |